StockDrifts LogoStockDrifts

Mgen Solution 032790

Company
엠젠솔루션Mgen Solution
Insiders
1
Buys
0
Total Value
₩70M ($48K)
Avg Return
+65.96%
Last Filing
2024-06-25

Mgen Solution (032790) has 0 disclosed insider purchases and 1 disclosed disposals on record, filed by 1 distinct insiders. Together those filings cover ₩70M ($48K) in reported transaction value. The earliest filing StockDrifts holds for Mgen Solution is dated 2023-09-27; the most recent is 2024-06-25. Across these filings the average return since disclosure is +65.96%, measured from each filing date to the latest available close.

Price & insider activity (12 months)

Recent insider trades

DateTypeSourceInsiderPositionSharesPrice at filingReturnValue
2026-09-01BUY신규선임
전흥재
Jeonheungjae
president232.8K---
2024-06-25BUYCB인수
트렌스젠바이오
Transgenbio
largest shareholder405.3K₩1,467-51.5%₩595M ($413K)
2023-12-22SELL기타
트렌스젠바이오
Transgenbio
largest shareholder-218₩1,519+53.2%₩331K ($230)
2023-09-27SELLMarket Sell
황용규
Yonggyu Hwang
moving-33.3K₩2,089+66.0%₩70M ($48K)

Frequently asked questions

Who has been buying Mgen Solution stock?
1 distinct insiders have filed 0 disclosed insider purchases in Mgen Solution (032790), most recently on 2024-06-25. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.
How many insider filings does Mgen Solution have?
Mgen Solution has 0 buy-side and 1 sell-side disclosures on record, covering ₩70M ($48K) in total reported value, spanning 2023-09-27 to 2024-06-25.
Do insider buys in Korean stocks predict returns?
Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean regulatory filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

More on this data

Every trade listed above comes from an official regulatory disclosure. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.